祛风止咳汤联合孟鲁斯特钠治疗咳嗽变异性哮喘(CVA)随机平行对照研究

Qufengzhike Decoction combined with Montelukast Sodium in the Treatment of Cough Variant Asthma(CVA) Randomized Controlled Study

[目的]观察祛风止咳汤联合孟鲁斯特钠治疗咳嗽变异性哮喘(CVA)疗效。[方法]使用随机平行对照方法,将80例住院患者按随机数字表方法简单随机分两组。对照组40例孟鲁斯特钠,10mg/次,1次/d。治疗组40例祛风止咳汤(紫苏子、前胡、紫苏叶、蝉蜕、牛蒡子、枇杷叶、炙麻黄、地龙各10g,五味子5g),清水浸泡,1剂/d,水煎150mL,2次/d;孟鲁斯特钠治疗同对照组。连续治疗2周为1疗程。观测临床症状、症候积分、FEV_1、FEV_1%pred、FEV_1/FVC、PEF%pred、不良反应。治疗1疗程,判定疗效。[结果]治疗组显效26例,有效12例,无效2例,总有效率95.00%;对照组显效18例,有效13例,无效9例,总有效率77.50%;治疗组疗效优于对照组(P<0.05)。症候积分治疗组降低优于对照组(P<0.01)。FEV_1、FEV_1%pred、FEV_1/FVC、PEF%pred治疗组改善优于对照组(P<0.01)。[结论]祛风止咳汤联合孟鲁斯特钠治疗咳嗽变异性哮喘(CVA),疗效满意,无严重不良反应,值得推广。

[Objective] Observation of Qufengzhike decoction combined with montelukast sodium in the treatment of cough variant asthma （CVA） effect. [Method] Using random parallel control method, 80 cases of hospitalized patients were randomly divided into two groups randomly. The method is simple and the control group of 40 cases of montelukast sodium, lOmg/times, 1 times and 40 cases in/d. group were Qufengzhike decoction （perilla seed, peucedanum, perilla leaf, cicada, burdock, loquat leaf, fried ephedra, earthworm the log）, Schisandra water immersion, 1 doses of/d, decoction 150mL, 2 times/d; western medicine treatment with the control group. 2 weeks of continuous treatment for 1 course of treatment. Observe the clinical symptoms, symptom score, FEV1, FEVl%, PRED, FEV1/FVC, PEF%, pred , adverse reaction. Treatment of 1 courses of treatment, determine efficacy. [Result] The treatment group 26 cases, 12 cases were effective, 2 cases ineffective, the total efficiency of 95%; the control group was 18 cases, 13 cases were effective, 9 cases ineffective, the total efficiency of 77.50%; the treatment group than the control group （P〈0.05）. Symptom score in treatment group was lower than that in the control group （P〈0.01）. FEV1 FEV1, pred FEV1/FVC, PEF% PRED%, the treatment group was better than the control group （e〈0.01）. [Conclusion] Qufengzhike decoction combined with montelukast sodium in the treatment of cough variant asthma （CVA）, satisfactory curative effect, no serious adverse reactions, worthy of promotion.